Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)

Background and Wady aims : Vedolizumab (VDZ) is a gutselective integrin inhibitor used to treat Crohn's disease (CD) and ulcerative colitis (UC). This retrospective study assessed effectiveness and treatment persistence of VDZ in a Belgian real-life cohort of CD and UC patients. Patients and methods : CD and UC patients from IS Belgian centers, who started VDZ between 01/09/2015 and 31/06/2016 and attended >= 1 visit after the first VDZ Infusion, were included. Data were collected before first infusion, at week (W)10, W14 (CD patients only), month (M)6 and last follow-up. Treatment response and remission rates (changes in disease activity scores) and treatment persistence (Kaplan-Meier analysis) were assessed. Results : Of the 348 patients receiving at least one dose of VDZ, 325 (202 CD, 45 biologic-naive: and 123 UC, 42 biologic-naive) patients were included in data analyses. At M6, 87.6% (176/201) of CD and 86.1% (105/122) of UC patients were still on VD7, treatment, 75.6% (34/45) and 83.9% (26/31) achieved clinical response, and 66.7% (44/66) and 42.9% (15/35) were in remission. At M6 remission rates was significantly higher while response rates tended to be higher among biologic-naive versus biologic-failure CD patients. Conclusions : VDZ offers an effective treatment option in reallife settings and treatment effectiveness appears higher in biologicnaive versus biologic-failure CD patients.